What is the recommended management for a pregnant patient with suspected HELLP syndrome?

Management of HELLP Syndrome in Pregnancy

Delivery is the definitive treatment for HELLP syndrome, with timing dependent on gestational age: immediate delivery at ≥34 weeks, and consideration of expectant management with corticosteroids for fetal lung maturation only between 24-34 weeks in carefully selected stable cases. 1

Initial Stabilization and Diagnosis Confirmation

HELLP syndrome represents a severe manifestation of preeclampsia requiring urgent recognition and management. The syndrome is defined by hemolysis, elevated liver enzymes, and thrombocytopenia, and should be considered part of the preeclampsia spectrum rather than a separate disorder 1. Key diagnostic features include:

• Laboratory confirmation: Lactate dehydrogenase ≥600 IU/L (present in 68% of cases), AST ≥70 IU/L (94% of cases), and platelets <100 × 10⁹/L (93% of cases) 2, 3
• Clinical presentation: Abdominal pain (78%), hypertension (65%), nausea/vomiting (36%), and headache (29%) are the most common presenting symptoms 3
• Maternal complications occur in 45% of cases, most commonly hepatic (23%), central nervous system (20%), and respiratory (20%) complications 3

Blood Pressure Management

Maintain blood pressure below 155/105 mmHg using first-line agents 2:

• Intravenous labetalol
• Oral nifedipine (avoid sublingual route)
• Intravenous hydralazine 1

Seizure Prophylaxis

Administer magnesium sulfate for eclampsia prevention in all cases of HELLP syndrome, as this represents severe preeclampsia with end-organ involvement 1. This is universally recommended across international guidelines for women with severe features of preeclampsia 1.

Gestational Age-Based Delivery Timing

At ≥34 Weeks Gestation

Proceed with delivery immediately after maternal stabilization 1, 2. The mode of delivery should preferentially be vaginal if feasible 1, 4, 2. If the cervix is unfavorable, cervical ripening followed by labor induction is reasonable 2.

Between 24-34 Weeks Gestation

Administer a single course of corticosteroids for fetal lung maturation (either betamethasone 12 mg × 2 doses 24 hours apart, or dexamethasone 6 mg × 4 doses 12 hours apart), then proceed with delivery 1, 2, 5.

Conservative expectant management beyond 48 hours is controversial and should only be considered in highly selected stable cases with intensive monitoring 4, 2. However, delivery should proceed immediately if:

• Maternal condition deteriorates 2
• Fetal distress develops 2
• The patient is at or beyond 34 weeks 1, 2

Before 24 Weeks Gestation

Pregnancy termination is typically indicated, as perinatal mortality reaches 73% and maternal complications are life-threatening 3. Early-onset HELLP before 23 weeks has a 48% association with antiphospholipid syndrome, warranting evaluation 3.

Corticosteroid Controversy for Maternal HELLP Treatment

The evidence regarding corticosteroids specifically for maternal HELLP treatment (beyond fetal lung maturation) remains controversial:

• Six guidelines specifically advised against steroids for maternal HELLP syndrome 1
• One guideline (France 2016) suggested corticosteroids could be used for severe thrombocytopenia 1
• Some advocate for aggressive high-dose dexamethasone as cornerstone therapy (Mississippi Protocol) 6, 5
• Standard corticosteroid treatment for maternal HELLP is of uncertain clinical value 4, 2

Given the conflicting evidence and guideline recommendations against routine maternal corticosteroid therapy, limit corticosteroids to fetal lung maturation only between 24-34 weeks 1. Avoid high-dose treatment and repeated doses due to potential long-term adverse fetal neurodevelopmental effects 2.

Adjunctive Therapies

Therapeutic Plasma Exchange (TPE)

TPE is not first-line therapy but may be considered for refractory postpartum HELLP (Category III indication) when patients fail to respond to standard management within 24 hours 7. TPE showed significant improvement in platelet counts and lactate dehydrogenase levels in one series, though it remains a lower-category indication 7.

Blood Product Support

• Platelet transfusion for severe thrombocytopenia, particularly if invasive procedures are needed 5
• Monitor coagulation status closely with repeat testing if clinical presentation changes 8

Postpartum Monitoring

Continue intensive surveillance for at least 48 hours postpartum, as:

• 30% of HELLP cases develop postpartum (majority within 48 hours) 4, 2
• Hypertension commonly worsens between days 3-6 postpartum 1
• Preeclampsia may worsen or appear de novo after delivery 1

Critical Pitfalls to Avoid

• Do not delay delivery at ≥34 weeks attempting conservative management 2
• Do not use sublingual nifedipine for blood pressure control 1
• Avoid renin-angiotensin system blockers, atenolol, and diuretics (except for chronic hypertension) 1
• Do not miss underlying antiphospholipid syndrome in early-onset cases (<23 weeks), present in 48% 3
• Monitor for hemophagocytic syndrome if prolonged hemocytopenia and thrombocytopenia persist beyond expected HELLP recovery 8
• Obtain neuroimaging (CT/MRI) for any neurological alarm signs, as intracerebral hemorrhage is a life-threatening complication 8, 3